This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MDRNA, Affymetrix: Early Volume Plays

NEW YORK ( TheStreet) -- Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

MDRNA (MRNA) opened higher by 84 cents, or 88.6%, to $1.79 after the company reported potent anti-tumor activity against both liver and bladder cancers via both systemic and local delivery with its proprietary UsiRNAs delivered by its novel DiLA2 platform. The 50-day average daily volume for MDRNA is 292,000, according to the Nasdaq.

Hythiam (HYTM) jumped by 3 cents, or 6.6%, to 54 cents at the start of trading after a published paper sponsored by the company noted predictive models that can be utilized as the basis for Hythiam to develop new and innovative approaches for substance dependence solutions that result in improved member care and reduced costs for payors. The 50-day average daily volume for Hythiam is 1.02 million.

LeCroy (LCRY) rallied by 47 cents, or 13%, to $4.08 in early trading after the company said it expects fiscal second quarter revenue of approximately $31 million, which is above the $29.9 million average of two analyst estiamtes. The 50-day average daily volume for LeCroy is 25,000.

Affymetrix (AFFX) slumped by 74 cents, or 11.5%, to $5.70 in early trading after Barclays downgraded the stock to underweight from equal weight. The firm also lowered its price target on Affymetrix to $3 from $6. The 50-day average daily volume for Affymetrix is 1.24 million.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRNA $0.20 -12.49%
AFFX $14.01 0.14%
AAPL $92.38 -0.92%
FB $119.07 1.10%
GOOG $708.11 0.95%


Chart of I:DJI
DOW 17,679.20 +18.49 0.10%
S&P 500 2,044.85 -5.78 -0.28%
NASDAQ 4,695.1520 -21.9420 -0.47%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs